Melanoma Metastasized to the Brain and Steroids
Efficacy of Immunotherapy in Melanoma Patients With Brain Metastases Treated With Steroids
Inge Marie Svane
80 participants
Jun 6, 2018
INTERVENTIONAL
Conditions
Summary
This clinical trial is to clarify whether treatment with a checkpoint inhibitor alone (pembrolizumab) or two in combination (ipilimumab and nivolumab), results in clinical benefit for MM patients with brain metastases and in need of steroid treatment. Patients will be treated in four arms depending on steroid dose level at inclusion (\> 10 \< 25 mg prednisolone or \> 25 mg prednisolone) and treatment (pembrolizumab alone or the combination of ipilimumab and nivolumab).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Alone
In combination with nivolumab.
In combination with ipilimumab.
In combination with binimetinib
In combination with encorafenib
In combination with dabrafenib
In combination with trametinib
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03563729